3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
48
Nivolumab
22
Cyclophosphamide
10
Carboplatin
10
spartalizumab
8
atezolizumab
7
Gemcitabine
7
130-nm albumin-bound paclitaxel
7
fludarabine
6
Cisplatin
6
Ipilimumab
5
durvalumab
4
budigalimab
4
avelumab
4
Pemetrexed
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Irinotecan
4
Interleukin-2
4
Immune Checkpoint Inhibitors
4
Docetaxel
4
Bevacizumab
4
cemiplimab
3
cabozantinib
3
aldesleukin
3
Standard of Care
3
Specimen Handling
3
Oxaliplatin
3
Fluorouracil
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
tinostamustine
×
Thoracic
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts